

Clinical Policy: Cabotegravir/rilpivirine (Cabenuva)

Reference Number: IL.PHAR.600

Effective Date: 05.01.22.

Last Review Date: 4.19.22

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Cabotegravir/rilpivirine (Cabenuva[®]) is a 2-drug co-packaged product of cabotegravir and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).

FDA Approved Indication(s)

Cabenuva is indicated for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 ribonucleic acid (RNA) less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Cabenuva is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. HIV-1 Infection (must meet all):

1. Request is for Cabenuva;
2. Confirmed diagnosis of HIV-1;
3. Age \geq 12 years; Member weighs \geq 35 kg;
4. Documentation of adherence to a stable oral antiretroviral regimen for HIV-1 for \geq 3 months;
5. Documentation of sustained virologic suppression as evidenced by HIV RNA viral load $<$ 50 copies/mL for \geq 3 months;
6. Member has no history of treatment failure (*see Appendix D*);
7. Member has no known or suspected resistance to either cabotegravir or rilpivirine;
8. Member agree to required monthly injection dosing schedule and is counseled on importance of adherence;
9. Dose does not exceed (a or b):
 - a. Monthly schedule: 600 mg cabotegravir and 900 mg rilpivirine (1 kit of 2 vials) initiation dose,* followed by 400 mg cabotegravir and 600 mg rilpivirine (1 kit of 2 vials) every month thereafter;
**A initiation dose may be repeated if member misses more than 2 monthly scheduled continuation injections*
 - b. Every 2-month schedule: 600 mg cabotegravir and 900 mg rilpivirine (1 kit of 2 vials) 1 month apart for 2 consecutive months (initial dose), followed by 600 mg cabotegravir and 900 mg rilpivirine (1 kit of 2 vials) every 2 months thereafter.

POLICY TITLE**Approval duration: 6 months****B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

II. Continued Therapy**A. HIV-1 Infection** (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Cabenuva for HIV-1 infection and has received this medication for at least 30 days;
2. Patient shows consistent monthly medication use within the last 6 months;
3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed (a, b, or c):
 - a. 400 mg cabotegravir and 600 mg rilpivirine (1 kit of 2 vials) every month;
 - b. 600 mg cabotegravir and 900 mg rilpivirine (1 kit of 2 vials) every 2 months;
 - c. If member has missed injections (≥ 2 injections if on monthly schedule or just one injection if on every 2-month schedule) as evidenced by claims history, both of the following (i and ii):
 - i. Provider attestation that member remains an appropriate candidate for therapy;
 - ii. Follow recommended dosing schedule for missed injections (*see Appendix F*).

Approval duration: 12 months**B. Other diagnoses/indications:**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information*Appendix A: Abbreviation/Acronym Key*

HIV-1 - human immunodeficiency virus type-1

INSTI - integrase strand transfer inhibitor

NNRTI - non-nucleoside reverse transcriptase inhibitor

ART – antiretroviral therapy

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

POLICY TITLE

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
emtricitabine and tenofovir disoproxil fumarate (Truvada)	PrEP: One tablet (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) PO QD	Refer to prescribing information

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Cabenuva: previous hypersensitivity to Cabenuva or any of its components, coadministration with uridine diphosphate (UDP)-glucuronosyl transferase (UGT)1A1 and/or cytochrome P450(CYP)3A4 enzyme induction drugs for which significant decreases in cabotegravir and/or rilpivirine plasma concentrations may occur, which may result in loss of virologic response
- Boxed warning(s):
 - Cabenuva: none reported

Appendix D: General Information

Per the Department of Health and Human Services Antiretroviral Guidelines:

- Evaluation of virologic failure should include assessment of adherence, drug-drug and drug-food interactions, drug tolerability, HIV RNA, and CD4 T lymphocyte cell count trends over time, treatment history, and prior and current drug-resistance testing results.
- Virologic failure is defined as the inability to achieve or maintain suppression of viral replication to HIV RNA level < 200 copies/mL. Patients with levels persistently above 200 copies/mL, especially > 500 copies/mL, often develop drug resistance.
- Panel's recommendation: Cabenuva can be used after oral lead-in therapy to replace an existing oral antiviral regimen in people with HIV with sustained viral suppression for 3 to 6 months (optimal duration is not defined) who have good adherence and engagement in care, no baseline resistance to either medication, no prior virologic failures (AI recommendation).

Appendix E: Examples of Bone/Renal Co-morbidities and Risk Factors

Examples include, but are not limited to:

- Bone disease: osteoporosis, osteopenia, receiving chronic corticosteroids or other therapies known to decrease bone density (e.g., aromatase inhibitors, androgen deprivation therapy, doxorubicin, cyclophosphamide), frail/underweight
- Renal disease: chronic kidney disease, estimated creatinine clearance < 60 mL/min, albuminuria, family history of kidney disease, diabetes, receiving nephrotoxic medications

V. Dosage and Administration

POLICY TITLE

Drug Name	Indication	Dosing Regimen	Maximum Dose
Cabenuva	HIV-1 infection	<p>Prior to initiating treatment, oral lead-in dosing may be considered to assess the tolerability of cabotegravir and rilpivirine with the recommended dosage used for approximately 1 month.</p> <p><u>Monthly Dosing Schedule</u> Initiate with 600 mg cabotegravir and 900 mg rilpivirine IM on the last day of current antiretroviral therapy or oral lead-in and continue with IM injections of 400 mg cabotegravir and 600 mg rilpivirine every month thereafter.</p> <p><u>Every 2 Month Dosing Schedule</u> Initiate with 600 mg cabotegravir and 900 mg rilpivirine IM on the last day of current antiretroviral therapy or oral lead-in for 2 consecutive months, then continue with IM injections every 2 months thereafter.</p>	<p>400 mg cabotegravir and 600 mg rilpivirine every month</p> <p>OR</p> <p>600 mg cabotegravir and 900 mg rilpivirine every 2 months</p>

VI. Product Availability

Injectable suspension kits:

- Cabenuva 400 mg/600 mg kit: cabotegravir 400 mg/2 mL (200 mg/mL) vial / rilpivirine 600 mg/2mL (300 mg/mL) vial
- Cabenuva 600 mg/900 mg kit: cabotegravir 600 mg/3 mL (200 mg/mL) vial / rilpivirine 900 mg/3mL (300 mg/mL) vial
 -

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2018, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0741	Injection, cabotegravir and rilpivirine, 2 mg/3mg
C9399, J3490	Injection, cabotegravir extended-release

POLICY TITLE

References

1. Cabenuva Prescribing Information. Research Triangle Park, NC: GlaxoSmithKine; January 2022. Available at: www.cabenuva.com. Accessed February 2, 2022.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/>. Last updated August 16, 2021. Accessed January 4, 2022.
3. Centers for Disease Control and Prevention, U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021. Available at: <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf>. Accessed January 11, 2022.

Reviews, Revisions, and Approvals	Date	Approval Date
Original approval date		
New Policy Created for migration to HFS PDL	9.30.21	
1Q 2021: Removed co-administered with other ART medications; updated dosing information; reworded the criteria initiated on oral Vocabria and Edurant; Separate the criteria for no history of treatment failure, and no known or suspected resistance to cabotegravir and rilpivirine; added adherence to a stable oral antiretroviral for more than 3 months; Updated ≥ 6 months to ≥ 3 months for RNA viral load < 50 copies/mL; updated product availability; added Appendix E: Examples of Bone/Renal Co-morbidities and Risk Factors; updated Appendix D: General Information; added <i>Appendix B: Therapeutic Alternatives</i>	3.11.22	
2Q 2022: removal of oral lead-doses of Vocabria and Endurant requirement for Cabenuva per updated PI; added pediatric extension for age 12 years of age and older and weighing at least 35 kgs for Cabenuva per updated PI.	4.19.22	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

POLICY TITLE

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

POLICYTITLE

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.